Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells.
Vascular endothelial growth factor (VEGF) is induced by stress. We determined whether chemotherapy (genotoxic stress) could induce expression of VEGF and VEGF receptors (VEGFR) in human colorectal cancer cells. The colorectal cancer cell lines HT29, RKO, and HCT116 were acutely exposed to increasing doses of oxaliplatin or 5-fluorouracil for 2, 6, and 24 h in vitro. Expression of VEGF ligand family members, VEGFRs, and signaling intermediates was determined by reverse transcription-PCR and Northern and Western blotting. The effect of oxaliplatin on VEGF-A transcriptional activity was determined by promoter assays. Acute exposure of human colorectal cancer cells to oxaliplatin led to a marked induction of VEGF-A mRNA and protein, whereas 5-fluorouracil alone or when added to oxaliplatin did not cause a further increase in VEGF levels. VEGF-A promoter activity was induced by oxaliplatin exposure. Expression of VEGF-C, placental growth factor, VEGFR-1, and neuropilin-1 levels were also increased when cells were treated with oxaliplatin. Oxaliplatin led to an increase in Akt and Src activation in HT29 cells. In contrast, Akt activation did not change in RKO cells whereas phospho-Src and phospho-p44/42 mitogen-activated protein kinase was dramatic increased by oxaliplatin. Inhibition of Akt or Src activation with wortmannin or PP2 blocked induction of VEGF-A by oxaliplatin in HT29 or RKO cells, respectively. VEGFRs may reflect the adaptive stress responses by which tumor cells attempt to protect themselves from genotoxic stress. Neutralization of prosurvival responses with anti-VEGF therapy might explain, in part, some of the beneficial effects of anti-VEGF therapy when added to chemotherapy.
Fan
Fan
F
Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77230-1402, USA.
Gray
Michael J
MJ
Dallas
Nikolaos A
NA
Yang
Anthony D
AD
Van Buren
George
G
Camp
E Ramsay
ER
Ellis
Lee M
LM
D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000473:pathology*; D017077:Culture Media, Conditioned; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006207:Half-Life; D006801:Humans; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D000077150:Oxaliplatin; D000072483:Placenta Growth Factor; D011257:Pregnancy Proteins / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D040262:Receptors, Vascular Endothelial Growth Factor / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D014158:Transcription, Genetic / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics* / Q000378:metabolism; D042561:Vascular Endothelial Growth Factor B / Q000235:genetics / Q000378:metabolism; D042582:Vascular Endothelial Growth Factor C / Q000235:genetics / Q000378:metabolism
D000970:Antineoplastic Agents; D017077:Culture Media, Conditioned; D009944:Organoplatinum Compounds; C000608036:PGF protein, human; D011257:Pregnancy Proteins; D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A; D042561:Vascular Endothelial Growth Factor B; D042582:Vascular Endothelial Growth Factor C; D000077150:Oxaliplatin; D000072483:Placenta Growth Factor; D040262:Receptors, Vascular Endothelial Growth Factor
FASEB J. 2003 Mar;17(3):446-8
12551841
Clin Cancer Res. 2006 May 1;12(9):2706-15
16675562
Cancer Res. 2005 Jan 1;65(1):195-202
15665295
Oncogene. 2005 Apr 14;24(16):2647-53
15735759
Angiogenesis. 2001;4(2):155-62
11806247
Mol Cancer Ther. 2003 Aug;2(8):753-63
12939465
Semin Oncol. 2006 Oct;33(5 Suppl 10):S1-7
17145519
Cancer Res. 1996 Sep 1;56(17):3891-4
8752153
FEBS Lett. 2006 May 22;580(12):2879-87
16631753
Mol Cancer Ther. 2006 Aug;5(8):2070-7
16928828
Cancer. 2005 Jul 15;104(2):427-38
15952180
J Natl Cancer Inst. 2008 Jan 16;100(2):109-20
18182619
N Engl J Med. 2006 Dec 14;355(24):2542-50
17167137
N Engl J Med. 2004 Jun 3;350(23):2335-42
15175435
Oncogene. 2001 Jun 21;20(28):3751-6
11439338
J Clin Oncol. 2005 Feb 10;23(5):1011-27
15585754
N Engl J Med. 2007 Dec 27;357(26):2666-76
18160686
Cancer Res. 1999 Oct 1;59(19):4804-7
10519388
Cancer Res. 2006 Nov 15;66(22):10953-8
17108133
Curr Biol. 2003 Sep 30;13(19):1721-7
14521839
Cancer. 2002 Feb 15;94(4):934-9
11920461
Cancer Res. 2001 Aug 1;61(15):5736-40
11479209
Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):768-72
7531342
J Clin Oncol. 2004 Jun 1;22(11):2092-100
15123733